Log in

NASDAQ:ADMA - ADMA Biologics Stock Price, Forecast & News

$4.32
+0.19 (+4.60 %)
(As of 12/8/2019 01:01 AM ET)
Today's Range
$4.07
Now: $4.32
$4.35
50-Day Range
$4.00
MA: $4.56
$5.16
52-Week Range
$2.08
Now: $4.32
$6.31
Volume834,442 shs
Average Volume870,241 shs
Market Capitalization$256.25 million
P/E RatioN/A
Dividend YieldN/A
Beta2.66
ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADMA
CUSIPN/A
Phone201-478-5552

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.99 million
Book Value$0.43 per share

Profitability

Net Income$-65,740,000.00
Net Margins-260.92%

Miscellaneous

Employees314
Market Cap$256.25 million
Next Earnings Date3/11/2020 (Estimated)
OptionableOptionable

Receive ADMA News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMA and its competitors with MarketBeat's FREE daily newsletter.


ADMA Biologics (NASDAQ:ADMA) Frequently Asked Questions

What is ADMA Biologics' stock symbol?

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

How were ADMA Biologics' earnings last quarter?

ADMA Biologics Inc (NASDAQ:ADMA) posted its quarterly earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.23) by $0.04. The biotechnology company had revenue of $7.22 million for the quarter, compared to analyst estimates of $5.71 million. ADMA Biologics had a negative net margin of 260.92% and a negative return on equity of 203.21%. View ADMA Biologics' Earnings History.

When is ADMA Biologics' next earnings date?

ADMA Biologics is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for ADMA Biologics.

What price target have analysts set for ADMA?

6 brokers have issued 12 month price objectives for ADMA Biologics' stock. Their forecasts range from $4.00 to $14.00. On average, they anticipate ADMA Biologics' share price to reach $10.20 in the next twelve months. This suggests a possible upside of 136.1% from the stock's current price. View Analyst Price Targets for ADMA Biologics.

What is the consensus analysts' recommendation for ADMA Biologics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ADMA Biologics.

What are Wall Street analysts saying about ADMA Biologics stock?

Here are some recent quotes from research analysts about ADMA Biologics stock:
  • 1. Maxim Group analysts commented, "ADMA announced (8/22) that the relaunch of BIVIGAM has commenced. BIVIGAM is available through authorized distributor BioCareSD (Private). Launch for ASCENIV should follow in 2H19." (8/27/2019)
  • 2. HC Wainwright analysts commented, "We note that Perceptive Credit Holdings is an investment entity of Perceptive Life Advisors, which is one of ADMA’s largest institutional shareholders. In our view, Perceptive’s extension of credit to ADMA underscores the investor’s confidence in the company." (2/21/2019)

Has ADMA Biologics been receiving favorable news coverage?

Media stories about ADMA stock have been trending extremely negative on Saturday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. ADMA Biologics earned a daily sentiment score of -4.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for ADMA Biologics.

Are investors shorting ADMA Biologics?

ADMA Biologics saw a drop in short interest in November. As of November 15th, there was short interest totalling 4,990,000 shares, a drop of 5.3% from the October 31st total of 5,270,000 shares. Based on an average daily trading volume, of 782,600 shares, the days-to-cover ratio is presently 6.4 days. Approximately 11.0% of the shares of the company are short sold. View ADMA Biologics' Current Options Chain.

Who are some of ADMA Biologics' key competitors?

What other stocks do shareholders of ADMA Biologics own?

Who are ADMA Biologics' key executives?

ADMA Biologics' management team includes the folowing people:
  • Mr. Adam S. Grossman, Co-Founder, Pres, CEO & Director (Age 42)
  • Dr. Jerrold B. Grossman Ph.D., D.P.S., Co-Founder & Vice Chairman (Age 71)
  • Mr. Brian Lenz CPA, CPA, Exec. VP & CFO (Age 47)
  • Dr. James Mond, Exec. VP, Chief Scientific Officer & Chief Medical Officer (Age 73)
  • Mr. James Hauert, Sr. VP of Commercialization & Strategy

Who are ADMA Biologics' major shareholders?

ADMA Biologics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (1.45%), State Street Corp (1.17%), Barclays PLC (0.72%), California State Teachers Retirement System (0.13%), Rhumbline Advisers (0.08%) and Phoenix Holdings Ltd. (0.06%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Biotest Divestiture Trust, Brian Lenz, James Mond, Jerrold B Grossman, Lawrence P Guiheen and Life Sciences Maste Perceptive. View Institutional Ownership Trends for ADMA Biologics.

Which major investors are selling ADMA Biologics stock?

ADMA stock was sold by a variety of institutional investors in the last quarter, including Tower Research Capital LLC TRC. View Insider Buying and Selling for ADMA Biologics.

Which major investors are buying ADMA Biologics stock?

ADMA stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Barclays PLC, State Street Corp, California State Teachers Retirement System, Phoenix Holdings Ltd., Metropolitan Life Insurance Co NY, Rhumbline Advisers and Voya Investment Management LLC. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, James Mond, Jerrold B Grossman, Lawrence P Guiheen and Life Sciences Maste Perceptive. View Insider Buying and Selling for ADMA Biologics.

How do I buy shares of ADMA Biologics?

Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ADMA Biologics' stock price today?

One share of ADMA stock can currently be purchased for approximately $4.32.

How big of a company is ADMA Biologics?

ADMA Biologics has a market capitalization of $256.25 million and generates $16.99 million in revenue each year. The biotechnology company earns $-65,740,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. ADMA Biologics employs 314 workers across the globe.View Additional Information About ADMA Biologics.

What is ADMA Biologics' official website?

The official website for ADMA Biologics is http://www.admabiologics.com/.

How can I contact ADMA Biologics?

ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at 201-478-5552 or via email at [email protected]


MarketBeat Community Rating for ADMA Biologics (NASDAQ ADMA)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  327 (Vote Outperform)
Underperform Votes:  213 (Vote Underperform)
Total Votes:  540
MarketBeat's community ratings are surveys of what our community members think about ADMA Biologics and other stocks. Vote "Outperform" if you believe ADMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Featured Article: Why do commodities matter?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel